We're enrolling 9,000 pregnant women nationwide to provide blood samples for research creating better screening tests for pregnancy complications. Participate by getting three easy blood draws at your home, with compensation provided.
At home:
Currently enrolling up to 9,000 participants across the U.S. Total study duration is through pregnancy plus 3 months postpartum (approximately 9-12 months).
From home virtually across continental US: Available nationwide with 3 easy mobile phlebotomy to your home.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
A clinical trial is a research study that helps develop and test new medical treatments, devices, or tests to determine if they are safe and effective. This study is developing a screening test to predict preeclampsia risk early in pregnancy. Your participation provides the blood samples and health information needed to create and validate this test.
Natera, Inc. is the sponsor of this study. Natera is a CLIA certified clinical laboratory and diagnostics company focused on genetic testing across oncology, women’s health, and organ health. In this research, Natera is evaluating an investigational screening approach for preeclampsia using samples and data from study participants.
Lindus Health is a contract research organization that manages clinical trials. The team coordinates study recruitment, site and virtual operations, and data collection, which may involve mobile phlebotomy, virtual enrollment, and medical record collection for home based participation.
Preeclampsia affects about 5% - 8% of pregnancies and involves high blood pressure and other signs that typically appear after 20 weeks. It can lead to serious complications for mothers and babies. Earlier risk assessment may help clinicians consider preventive measures when appropriate. Better screening tools may help identify patients at higher risk sooner.
Your blood will be analyzed for cell-free DNA markers, proteins, and genetic factors that may predict preeclampsia risk. This study may sequence large parts of your DNA. Samples will be stored securely at Natera's CLIA-certified laboratory. This test has not been cleared or approved by the FDA - it is being developed through this research.
When you enroll, you'll sign an authorization allowing the study team to request records from your healthcare provider(s). You won't personally gather or submit records. The study team requests them at enrollment, throughout pregnancy, and after delivery (within 3 months postpartum, at least 6 weeks after birth).
Yes, at any time without penalty or effect on your medical care. You can request your samples be destroyed at any time during the study.
.svg)
.svg)
.svg)
.svg)
